COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH:

Key Record Dates Identifier: NCT03703050
Brief Title: Nivolumab for Pediatric and Adult Relapsing/Refractory ALK+ Anaplastic Large Cell Lymphoma, for Evaluation of Response in Patients With Progressive Disease (Cohort 1) or as Consolidative Immunotherapy in Patients in Complete Remission After Relapse (Cohort 2) (NIVO-ALCL)

First Submitted : October 9, 2018
First Submitted that Met QC Criteria : October 10, 2018
First Posted : October 11, 2018

Last Update Submitted that Met QC Criteria : February 10, 2020
Last Update Posted : February 12, 2020